Impact Assessment of Systemic Geometric Distortion in 1.5T Magnetic Resonance Imaging Simulation through Three-dimensional Geometric Distortion Phantom on Dosimetric Accuracy for Magnetic Resonance Imaging-only Prostate Treatment Planning

通过三维几何畸变模型评估1.5T磁共振成像模拟中系统性几何畸变对仅使用磁共振成像进行前列腺治疗计划的剂量学精度的影响

阅读:1

Abstract

AIMS: Magnetic resonance imaging (MRI)-only radiotherapy has emerged as a solution to address registration errors that can lead to missed dose delivery. However, the presence of systemic geometric distortion (SGD) stemming from gradient nonlinearity (GNL) and inhomogeneity of the main magnetic field (B(0)) necessitates consideration. This study aimed to quantitatively assess residual SGD in 1.5T MRI simulation using a three-dimensional (3D) geometric distortion phantom and evaluate its impact on dosimetric accuracy for retrospective prostate cancer patients. MATERIALS AND METHODS: Ten retrospective cases of prostate cancer patients treated with volumetric modulated arc radiotherapy (VMAT) were randomly selected. A geometric distortion phantom was scanned on a 1.5T MRI simulation using a 3D T1 volumetric interpolated breath-hold examination sequence, varying bandwidth (BW), and two-phase-encoding directions. Distortion maps were generated and applied to the original computed tomography (oriCT) plan to create a distorted computed tomography plan (dCT), and a dice similarity coefficient (DSC) was observed. Dosimetric accuracy was evaluated by recalculating radiation dose for dCT plans using identical beam parameters as oriCT. RESULTS: The SGD increased with distance from the isocenter in all series. DSC exceeded 0.95 for all plans except the rectum. Regarding GNL's impact on dosimetric accuracy, most mean percentage errors for clinical target volume, planning target volume, and both femurs were under 2% in all plans, except for the bladder and rectum. CONCLUSION: SGD pre-evaluation is crucial and should be incorporated into a quality assurance program to ensure effective MRI-simulation performance before MRI-only treatment planning for prostate cancer.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。